PrairieGold Venture Partners

Virtual Incision is a medical technology company focused on developing innovative robotic-assisted surgical devices, specifically targeting colon resection. The company has created the MIRA (Miniaturized In vivo Robotic Assistant) Platform, which is a pioneering miniaturized surgical robotic support device. This platform allows for efficient operating room setups in minutes, eliminating the need for cumbersome equipment handling such as draping or docking. By enhancing the surgical process, Virtual Incision aims to improve clinical outcomes while also addressing healthcare costs, positioning itself as a leader in the field of robotic-assisted surgery.

Virtual Incision is a medical technology company focused on developing innovative robotic-assisted surgical devices, specifically targeting colon resection. The company has created the MIRA (Miniaturized In vivo Robotic Assistant) Platform, which is a pioneering miniaturized surgical robotic support device. This platform allows for efficient operating room setups in minutes, eliminating the need for cumbersome equipment handling such as draping or docking. By enhancing the surgical process, Virtual Incision aims to improve clinical outcomes while also addressing healthcare costs, positioning itself as a leader in the field of robotic-assisted surgery.

Virtual Incision is a medical technology company focused on developing innovative robotic-assisted surgical devices, specifically targeting colon resection. The company has created the MIRA (Miniaturized In vivo Robotic Assistant) Platform, which is a pioneering miniaturized surgical robotic support device. This platform allows for efficient operating room setups in minutes, eliminating the need for cumbersome equipment handling such as draping or docking. By enhancing the surgical process, Virtual Incision aims to improve clinical outcomes while also addressing healthcare costs, positioning itself as a leader in the field of robotic-assisted surgery.

Virtual Incision is a medical technology company focused on developing innovative robotic-assisted surgical devices, specifically targeting colon resection. The company has created the MIRA (Miniaturized In vivo Robotic Assistant) Platform, which is a pioneering miniaturized surgical robotic support device. This platform allows for efficient operating room setups in minutes, eliminating the need for cumbersome equipment handling such as draping or docking. By enhancing the surgical process, Virtual Incision aims to improve clinical outcomes while also addressing healthcare costs, positioning itself as a leader in the field of robotic-assisted surgery.

Virtual Incision is a medical technology company focused on developing innovative robotic-assisted surgical devices, specifically targeting colon resection. The company has created the MIRA (Miniaturized In vivo Robotic Assistant) Platform, which is a pioneering miniaturized surgical robotic support device. This platform allows for efficient operating room setups in minutes, eliminating the need for cumbersome equipment handling such as draping or docking. By enhancing the surgical process, Virtual Incision aims to improve clinical outcomes while also addressing healthcare costs, positioning itself as a leader in the field of robotic-assisted surgery.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Agrivida, Inc. is a biotechnology company specializing in animal health and nutrition through the development of innovative feed additives for poultry, swine, dairy and beef cattle, and aquaculture. Founded in 2003 and based in Four Seasons, Missouri, Agrivida utilizes its proprietary GRAINZYME technology to produce enzymes directly within corn kernels, offering a natural and effective method to enhance animal diets. This platform enables the integration of beneficial enzymes such as phytase and glucanase, which improve nutritional efficiency and reduce the environmental impact of livestock production. Agrivida's solutions aim to promote healthier food production while delivering economic benefits to its clients in the agricultural sector.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Chronix Biomedical, Inc. is a molecular diagnostics company specializing in the development of laboratory-developed blood tests, known as liquid biopsy tests, for cancer and organ transplant monitoring. Founded in 1997 and headquartered in San Jose, California, the company has established laboratories in Brookings, South Dakota, and Göttingen, Germany. Chronix's products include the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, designed to detect organ rejection by quantifying transplant-specific DNA in plasma. The company employs proprietary technology to analyze circulating nucleic acids, allowing for the diagnosis and management of chronic diseases and cancer. Chronix aims to partner with various organizations to expand its DNA-based assays, which have the potential to improve the management of a wide range of cancers and other health conditions.

Agrivida, Inc. is a biotechnology company specializing in animal health and nutrition through the development of innovative feed additives for poultry, swine, dairy and beef cattle, and aquaculture. Founded in 2003 and based in Four Seasons, Missouri, Agrivida utilizes its proprietary GRAINZYME technology to produce enzymes directly within corn kernels, offering a natural and effective method to enhance animal diets. This platform enables the integration of beneficial enzymes such as phytase and glucanase, which improve nutritional efficiency and reduce the environmental impact of livestock production. Agrivida's solutions aim to promote healthier food production while delivering economic benefits to its clients in the agricultural sector.

ZeaChem is focused on developing sustainable alternatives to petroleum-based fuels and chemicals, utilizing renewable biomass sources such as wood chips, wheat straw, corn stover, and grasses. The company employs a proprietary fermentation process that converts all carbon in the sugars into end products, resulting in high yields and making its products competitive with traditional fossil fuels, even without subsidies. By targeting the $1 trillion chemicals and fuels markets, ZeaChem aims to provide high-margin solutions that address environmental concerns while maintaining economic viability.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Virtual Incision is a medical technology company focused on developing innovative robotic-assisted surgical devices, specifically targeting colon resection. The company has created the MIRA (Miniaturized In vivo Robotic Assistant) Platform, which is a pioneering miniaturized surgical robotic support device. This platform allows for efficient operating room setups in minutes, eliminating the need for cumbersome equipment handling such as draping or docking. By enhancing the surgical process, Virtual Incision aims to improve clinical outcomes while also addressing healthcare costs, positioning itself as a leader in the field of robotic-assisted surgery.

Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Orasi Medical is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. Initially, the company's aim was to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. They have since expanded their efforts towards developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases such as multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD).

Agrivida, Inc. is a biotechnology company specializing in animal health and nutrition through the development of innovative feed additives for poultry, swine, dairy and beef cattle, and aquaculture. Founded in 2003 and based in Four Seasons, Missouri, Agrivida utilizes its proprietary GRAINZYME technology to produce enzymes directly within corn kernels, offering a natural and effective method to enhance animal diets. This platform enables the integration of beneficial enzymes such as phytase and glucanase, which improve nutritional efficiency and reduce the environmental impact of livestock production. Agrivida's solutions aim to promote healthier food production while delivering economic benefits to its clients in the agricultural sector.

ZeaChem is focused on developing sustainable alternatives to petroleum-based fuels and chemicals, utilizing renewable biomass sources such as wood chips, wheat straw, corn stover, and grasses. The company employs a proprietary fermentation process that converts all carbon in the sugars into end products, resulting in high yields and making its products competitive with traditional fossil fuels, even without subsidies. By targeting the $1 trillion chemicals and fuels markets, ZeaChem aims to provide high-margin solutions that address environmental concerns while maintaining economic viability.

Chronix Biomedical, Inc. is a molecular diagnostics company specializing in the development of laboratory-developed blood tests, known as liquid biopsy tests, for cancer and organ transplant monitoring. Founded in 1997 and headquartered in San Jose, California, the company has established laboratories in Brookings, South Dakota, and Göttingen, Germany. Chronix's products include the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, designed to detect organ rejection by quantifying transplant-specific DNA in plasma. The company employs proprietary technology to analyze circulating nucleic acids, allowing for the diagnosis and management of chronic diseases and cancer. Chronix aims to partner with various organizations to expand its DNA-based assays, which have the potential to improve the management of a wide range of cancers and other health conditions.

Orasi Medical is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. Initially, the company's aim was to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. They have since expanded their efforts towards developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases such as multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD).

Augusta Systems, Inc. specializes in configurable technology platforms that facilitate the intelligent convergence of devices, systems, and networks. The company's award-winning EdgeFrontier products are designed to build and manage complex monitoring, control, and automation solutions. These solutions cater to various applications, including safety and security, energy and utility management, asset tracking, and building management. By enabling seamless collaboration and communication between enterprise networks and edge assets, such as sensors, actuators, wireless sensor networks, and imagery devices, Augusta Systems provides businesses with effective tools to enhance the protection and management of their operations.

iCentera is a leading provider of on-demand portal software focused on sales enablement. The company offers a web-based software as a service (SaaS) that enhances sales revenue by serving as a marketing, sales, and customer messaging platform. iCentera's solutions empower business users to create intranet sales portals, extranet channel partner portals, and customer portals, ensuring a consistent marketing voice throughout the organization. The software incorporates automated content management and built-in analytics to support sales teams effectively. With over 10,000 portals in operation, iCentera enables sales and partner organizations to optimize their performance. The company was acquired by CallidusCloud in June 2011.